An atypical hyperosmolar hyperglycemic state and diabetic ketoacidosis induced by sodium-glucose cotransporter-2 inhibitors: A case report

被引:1
作者
Wang, Chen-Ti [1 ]
Chang, Che-Wei [1 ]
Lu, Yung-Chuan [1 ]
Lam, Hing-Chung [1 ]
Ku, Shu-Ju [1 ]
Tseng, Kuo-Bin [2 ]
Kao, Yu-Hsi [1 ]
机构
[1] I Shou Univ, E Da Hosp, Dept Internal Med, Div Endocrinol & Metab, 1 Yida Rd, Kaohsiung 824, Taiwan
[2] I Shou Univ, E Da Canc Hosp, Dept Internal Med, Div Endocrinol & Metab, 21 Yida Rd, Kaohsiung 824, Taiwan
关键词
Atypical hyperosmolar hyperglycemic state; Diabetic ketoacidosis; Geriatrics; Sodium-glucose cotransporter-2 inhibitors; Type; 2; diabetes; MELLITUS; SGLT2; DAPAGLIFLOZIN; MORTALITY; SAFETY; CRISES;
D O I
10.1016/j.jfma.2019.11.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have become the best choice of second -line oral antidiabetic drugs for patients with heart or chronic kidney disease. However, it is not clear how safe this treatment is for elderly patients, especially Asians, who are known to be more insulin deficient than Caucasian individuals with a similar insulin resistance. Here, we report a case concerning an elderly patient with type 2 diabetes mellitus without insulin dependence, whose antidiabetic medication had recently been changed to include an SGLT-2 inhibitor. The patient presented with an atypical hyperosmolar hyperglycemic state and dia-betic ketoacidosis but recovered after insulin pump treatment and fluid supplementation. The patient was discharged with a prescription of a mixed-type insulin injection instead of oral antidiabetic medications for diabetes control. Our case demonstrates that if SGLT-2 inhibitors are administered to elderly Asian patients, their benefits and adverse effects should be care-fully monitored. Copyright (C) 2019, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
引用
收藏
页码:1325 / 1328
页数:4
相关论文
共 50 条
  • [41] Sodium-glucose cotransporter-2 inhibitors: an overview and perioperative implications
    Bardia, Amit
    Wai, Mabel
    Fontes, Manuel L.
    [J]. CURRENT OPINION IN ANESTHESIOLOGY, 2019, 32 (01) : 80 - 85
  • [42] Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes
    Handelsman, Yehuda
    [J]. ADVANCES IN THERAPY, 2019, 36 (10) : 2567 - 2586
  • [43] Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis
    Hampp, Christian
    Swain, Richard S.
    Horgan, Casie
    Dee, Elizabeth
    Qiang, Yandong
    Dutcher, Sarah K.
    Petrone, Andrew
    Tilney, Rong Chen
    Maro, Judith C.
    Panozzo, Catherine A.
    [J]. DIABETES CARE, 2020, 43 (01) : 90 - 97
  • [44] Sodium-glucose cotransporter-2 inhibitors and incidence of atrial fibrillation in older adults with type 2 diabetes: a retrospective cohort analysis
    Li, Yujia
    Tang, Huilin
    Guo, Yi
    Shao, Hui
    Kimmel, Stephen E.
    Bian, Jiang
    Schatz, Desmond A.
    Guo, Jingchuan
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [45] Sodium-glucose cotransporter-2 inhibitors for type 2 diabetes mellitus in adults: An overview of 46 systematic reviews
    Augusto, Gustavo A.
    Cassola, Nicolle
    Dualib, Patricia M.
    Saconato, Humberto
    Melnik, Tamara
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (10) : 2289 - 2302
  • [46] Hospitalization of Patients With Diabetes Due to Ketoacidosis Before and After the Initiation of Sodium-Glucose Cotransporter-2 Inhibitors
    Pikielny, Pnina Rotman
    Lurie, Tzipi Hornik
    Rabia, Razi
    Twito, Orit
    Rosenblum, Rachel Hava
    Yoseph, Liat Barzilay
    [J]. ENDOCRINE PRACTICE, 2023, 29 (09) : 686 - 691
  • [47] Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis
    Anan, Go
    Kikuchi, Daisuke
    Hirose, Takuo
    Ito, Hiroki
    Nakayama, Shingo
    Mori, Takefumi
    [J]. KIDNEY INTERNATIONAL REPORTS, 2023, 8 (04): : 925 - 928
  • [48] Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
    Heerspink, Hiddo J. L.
    Kosiborod, Mikhail
    Inzucchi, Silvio E.
    Cherney, David Z. I.
    [J]. KIDNEY INTERNATIONAL, 2018, 94 (01) : 26 - 39
  • [49] Sodium-glucose cotransporter-2 inhibitors: where and when?
    Cowie, Martin R.
    [J]. FUTURE CARDIOLOGY, 2020, 17 (03) : 403 - 406
  • [50] Sodium-Glucose Cotransporter-2 Inhibitors: Lack of a Complete History Delays Diagnosis
    Leslie, Bruce R.
    Gerwin, Leslie E.
    Taylor, Simeon I.
    [J]. ANNALS OF INTERNAL MEDICINE, 2019, 171 (06) : 421 - +